Perfusion imaging method

• US 20040081623A1
• Filed: 07/08/2003
• Published: 04/29/2004
• Est. Priority Date: 01/12/2001
• Status: Abandoned Application

• Current Assignee: GE Healthcare As (GE Healthcare Technologies, Inc.)
• Original Assignee: GE Healthcare As (GE Healthcare Technologies, Inc.)
• Inventors: Eriksen, Morten, Rasmussen, Henrik
• Application Number:
  US10/466,055
• Publication Number:
  US 20040081623A1
• Time in Patent Office: Days
• US Class Current: 424/9.52
• CPC Class Codes: A61B 8/481 involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream analysis of echo signal exploiting properties of a contrast enhancer in devices for short-range imaging with acoustic waves G01S7/52039

Abstract

This invention relates to ultrasound imaging, more specifically to a method of ultrasound investigation involving the use of an ultrasound contrast agent and administration of at least two gases or gas mixtures having different partial pressure of inert gas. The method may be used in assessing blood perfusion in tissue. A timed change of administered gases gives a subsequent change in contrast echogenicity. The gases are preferably administered by inhalation. The invention further relates to gas-microbubble containing ultrasound contrast agents used according to the method, and to kits to be used in assessments of tissue perfusion.

Claims

1. Method of ultrasound investigation of a human or non-human animal subject comprising

i) administering a gas-microbubble containing ultrasound contrast agent to said subject

ii) administering at least two gases or gas mixtures to said subject, said gases or gas mixtures having different partial pressure of inert gas, said gases or gas mixtures being administered either prior to, during and/or after the administration of said ultrasound contrast agent

iii) detecting ultrasound signals from said subject

iv) optionally, generating an image from said detected signals

2. Method as claimed in claim 1 wherein the investigation comprises an assessment of perfusion in tissues of said subject.

3. Method as claimed in claim 1 or 2 wherein said gases or gas mixtures are administrated by inhalation.

4. Method as claimed in any of claims 1-3 wherein said inert gas comprises any metabolically inert and biocompatible gas or mixture of gases;

preferably nitrogen, helium, argon, other noble gases, N₂O, or mixtures thereof;

most preferably nitrogen.

5. Method as claimed in any of claims 1-4 wherein the administration of a first gas or gas mixture is followed by the administering of a second gas or gas mixture, said second gas or gas mixture having a low partial pressure of inert gas when said first gas or gas mixture has a high pressure of inert gas, and having a high pressure of inert gas when said first gas or gas mixture has a low pressure of inert gas.

6. Method as claimed in claim 5 wherein said first gas or gas mixture has a low partial pressure of inert gas and wherein said second gas or gas mixture has a high partial pressure of inert gas.

7. Method as claimed in claims 5 or 6 wherein said first gas or gas mixture comprises oxygen and said second gas or gas mixture is room air.

8. Method as claimed in any of claims 5-7 wherein said high partial pressure of inert gas is between 75 and 85 kPa, preferably about 79 kPa and wherein said low partial pressure of inert gas is below 60 kPa, preferably below 40 kPa, more preferably below 20 kPa, most preferably below 5 kPa.

9. Method as claimed in any of claims 1-8 wherein said gas-microbubbles contain a gas of low water solubility, preferably fluorinated gases, more preferably fluorocarbons or sulfur hexafluoride, most preferably perfluoropropane, perfluorobutanes, perfluoropentanes and perfluorohexanes.

10. Method as claimed in any of claims 1-9 wherein said microbubbles are stabilised by a gas-stabilising material being selected from a coalescence-resistant surface membrane, preferred a filmogenic protein;

a polymer material, preferred polylactic acid, polyglycolic acid, or copolymers of polylactic and polyglycolic acid;

a non-polymeric and non-polymerisable wall-forming material; and

a surfactant, preferably one or more phospholipids.

11. Method as claimed in any of claims 1-10 wherein said gas-microbubbles are capable of developing a change in echogenicity upon contact with tissue having a partial pressure of inert gas different from the partial pressure of inert gas inside said microbubbles.

12. Method as claimed in any of claims 1-11 wherein said gas-microbubbles have a prolonged transit time through the tissues providing a sufficient gas exchange with said tissues.

13. Method as claimed in claim 12 wherein said prolonged transit time of microbubbles through the tissues is caused by at least transient increase in size of said microbubbles or by tissue-specific vectors located on the surface material of said microbubbles.

14. Method as claimed in claim 12 wherein said prolonged transit time of microbubbles is caused by the contrast agent being a combined preparation comprising a stabilised dispersed gas and a co-administered composition comprising a volatile component capable of evaporation in vivo into the dispersed gas so as at least transiently to increase the size of the microbubbles.

15. Method as claimed in any of claims 1-14 wherein administration of said gases or gas mixtures are controllably timed with the administration of said contrast agent.

16. Method as claimed in claim 15 wherein the administering of a first gas or gas mixture is followed by the administration of a second gas or gas mixture, and wherein the administration of said second gas is starting before, during or after administration of said ultrasound contrast agent.

17. Method as claimed in claim 16 wherein administration of said first gas or gas mixture has a duration of at least 5 minutes, preferably of at least 10 minutes.

18. Method as claimed in any of claims 16 or 17 wherein said first gas or gas mixture has a low partial pressure of inert gas and administering of said second gas or gas mixture is started 90 to 0 seconds before administering of said contrast agent, preferably 60 to 15 seconds before, and most preferably about 30 seconds before start of administering of the contrast agent.

19. Method as claimed in any of claims 1-18 wherein the contrast agent is administered by infusion followed by a bolus injection of the contrast agent.

20. Use of a gas-microbubble containing ultrasound contrast agent and at least two gases having different partial pressure of inert gas for the manufacturing of an ultrasound imaging agent for detecting ultrasound signals from a subject.

21. Use of an ultrasound imaging agent as claimed in claim 20 for use in assessing perfusion in tissue of a subject.

22. Use of an ultrasound imaging agent as claimed in claim 20 or 21 wherein said contrast agent is a combined preparation for simultaneous, separate or sequential use as a contrast agent in ultrasound imaging, said preparation comprising:

i) a first composition which is an injectable aqueous medium comprising dispersed gas microbubbles; and

ii) a second composition which is an injectable oil-in-water emulsion wherein the oil phase comprises droplets of a volatile component capable of evaporation in vivo into said dispersed gas microbubbles so as at least transiently to increase the size thereof.

23. Ultrasound imaging agent comprising a gas-microbubble containing ultrasound contrast agent and at least two gases or gas mixtures having different partial pressure of inert gas.

24. Kit comprising a gas-microbubble containing ultrasound contrast agent and at least two gases or gas mixtures having different partial pressure of inert gas.